Raj Vuppalanchi, MD
Internal Medicine · Indianapolis, INNPI 1588872923
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $254,269 of the $278,846 with a category attached, or 91.2%. 23 manufacturers reported payments, led by GSK at 33.2% of the total. 2025 is the largest year on record at $118,092, more than ten times the $672 reported in 2019. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $1810.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$93K
- Intercept Pharmaceuticals, Inc.$53K
- Madrigal Pharmaceuticals$23K
- Jazz Pharmaceuticals Inc.$20K
- Daiichi Sankyo Inc.$14K
- Echosens North America, Inc.$13K
- plus $62K from 17 others
Across 594 payments — averaging $5310.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$846K
- Eli Lilly$727K
- Novo Nordisk AS$360K
- Takeda Pharmaceuticals U.S.A., Inc.$307K
- Intercept Pharma Europe Ltd.$246K
- Intercept Pharmaceuticals, Inc.$193K
- plus $475K from 6 others
What the payments were for
- Consulting fees$254,26991%
- Speaking & faculty fees$16,7206%
- Travel & lodging$5,0892%
- Food & beverage$2,7681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 24 | $92,685 |
| Intercept Pharmaceuticals, Inc. | 8 | $53,250 |
| Madrigal Pharmaceuticals | 11 | $23,250 |
| Jazz Pharmaceuticals Inc. | 32 | $20,375 |
| Daiichi Sankyo Inc. | 4 | $13,635 |
| Echosens North America, Inc. | 13 | $13,366 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $10,651 |
| Agios Pharmaceuticals, Inc. | 8 | $9,301 |
| Eli Lilly | 3 | $8,438 |
| Ipsen Biopharmaceuticals, Inc | 3 | $8,223 |
| Merck | 9 | $7,969 |
| Gilead | 9 | $6,646 |
| Regeneron | 2 | $6,399 |
| Biomarin Pharmaceutical Inc. | 2 | $1,529 |
| Greenwich Biosciences, Inc. | 1 | $1,300 |
| Novo Nordisk AS | 3 | $639 |
| Perspectum Diagnostics Ltd | 5 | $611 |
| Sequana Medical US Inc. | 1 | $222 |
| Novo Nordisk | 2 | $135 |
| Fujifilm Healthcare Americas Corporation | 2 | $130 |
| La Jolla Pharmaceutical Company | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $30 |
| Johnson & Johnson | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$278,846 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 34 | $108,903 |
| RezdiffraResmetirom | 18 | $72,512 |
| CreonLipase/Protease/Amylase | 14 | $49,361 |
| Ursodiol | 54 | $14,550 |
| Mycophenolate Mofetil | 45 | $2,406 |
| PrevaliteCholestyramine | 14 | $1,027 |
| Spironolactone | 59 | $951 |
| Doxepin Hcl | 30 | $766 |
| Lactulose | 13 | $673 |
| EnuloseLactulose | 16 | $550 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 29 | $405 |
| Carvedilol | 35 | $208 |
| Furosemide | 33 | $117 |
| Omeprazole | 12 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $30 | $108,90334 claims |
| Madrigal PharmaceuticalsRezdiffra | $23,250 | $72,51218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Indianapolis
- Napoleon MamintaIndianapolis$116K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Awaneesh KumarIndianapolis$68K
- Justin FieldIndianapolis$49K
- Misty ShieldsIndianapolis$39K
- Volodymyr OliynykIndianapolis$38K
- Sapan BhutaIndianapolis$30K
- Azizullah BeranIndianapolis$29K
- Rachel WesterIndianapolis$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.